Sporanox patent ruling
Executive Summary
Trial court's ruling that Eon's generic Sporanox (itraconazole) does not infringe a Janssen patent affirmed by the Federal Circuit June 13. Eon launched its generic in February with 180 days of marketing exclusivity (1"The Pink Sheet" Feb. 14, 2005, In Brief)...
You may also be interested in...
Sporanox generic launches
Eon launches first generic of Janssen's antifungal Sporanox (itraconazole) Feb. 9. Eon, which holds 180-day marketing exclusivity on itraconazole 100 mg capsules, received ANDA approval in May but was barred from launching by a temporary restraining order in Janssen's patent infringement lawsuit (1"The Pink Sheet" June 7, 2004, In Brief). A federal judge ruled in July that Eon's ANDA does not infringe; the case is under appeal. Eon says it timed its launch for the start of the heavy prescribing season for itraconazole...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.